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Neurofibromin, the protein product of the neurofi- 
bromatosis type 1 @“I) gene, has two alternate iso- 
forms which are generated by alternative splicing of 
two exons. One of these isoforms containing exon 48a 
is expressed at highest levels in muscle. Since neurofi- 
bromin is a p21-ras regulator and has been recently 
shown to be modulated during Schwann cell differ- 
entiation, we examined the expression of the NFZ 
gene product during in vitro muscle differentiation. 
Previous work demonstrated that C,C,, murine my- 
oblast cell differentiation could be blocked by the in- 
troduction of an activated p21-ras protein. Using this 
model system, we demonstrate that differentiating 
C,C,, cells upregulate the expression of NFZ mRNA 
by 2 days of serum starvation concomitant with in- 
creased expression of nicotinic acetylcholine receptor 
mRNA. This upregulation of mRNA expression par- 
alleled an increase in neurofibromin and N-ras levels, 
but no change in the relative abundance of the iso- 
forms containing exon 23a or exon 48a was observed 
during in vitro myoblast differentiation. The increase 
in neurofibromin levels paralleled a decrease in the 
levels of activated p21-ras as assayed by in vivo 32P- 
orthophosphate incorporation into p21-ras. These re- 
sults suggest that in vitro C,C,, cell differentiation is 
associated with a concomitant increase in NFZ gene 
expression and decrease in the proportion of acti- 
vated p21-ras. 8 1994 Wiley-Liss, Inc. 
Key words: neurofibromin, muscle, tumor suppres- 
sor gene, ras oncogene 
INTRODUCTION 
Neurofibromatosis type 1 ( N F I )  is a common au- 
tosomal dominant disorder that manifests clinically with 
neurofibromas , cafe-au-lait spots, freckling in non-sun- 
exposed areas, Lisch nodules, optic pathway gliomas, 
skeletal abnormalities, and learning disabilities (Ric- 
cardi, 1991). The NF1 gene was identified by positional 
cloning and its protein product, neurofibromin, was 
found to be expressed in greatest amounts in brain, pe- 
ripheral nerve, Schwann cell, oligodendrocyte, adrenal 
gland, and spleen (Cawthon et al., 1990; Viskochil et 
al., 1990; Wallace et al., 1990; DeClue et al., 1991; 
Gutmann et al., 1991; Daston et al. ,  1992). Although the 
function of neurofibromin is largely unknown, it is a 
member of the GTPase activating protein (GAP) family 
of proteins which act to regulate p2 1 -ras by accelerating 
the conversion of the activc GTP-bound form of p21 -ras 
to the inactive GDP-bound form (Ballester et al., 1990; 
Martin et al., 1990; Xu et al., 1990). This function of 
neurofibromin may be critical to its function in Schwann 
cells (Basu et al., 1992; DeClue et al., 1992; Gutmann et 
al., 1993a). 
Recently, we have described the tissue distribution 
of one of the mRNA isoforms of N F I ,  termed type 3 NFZ 
or 3‘ALT, resulting from the insertion of an additional 
54 nucleotide exon into the extreme carboxyl terminus of 
the protein (Marchuk et al., 1991; Gutmann et al., 
1993b). This type 3 mRNA isoform is predominantly 
expressed in fetal and adult muscle tissues (Gutmann et 
al., 1993b). The expression of this isoform of N F l  in 
muscle suggested that neurofibromin may have a role in 
muscle differentiation different from its previously de- 
scribed functions in fibroblasts, Schwann cells, and brain 
tissue. It had been previously shown that overexpression 
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transfer onto Immobilon membranes. Alternatively, 
2-5 mg of total protein was immunoprecipitated using 10 
pg  of D1 antibody and collected on protein A-Sepharose 
beads (50% suspension; Pharmacia, Gaithersburgh, MD) 
before separation by SDS-PAGE. Immunoblotting was 
performed after blocking the membranes in 5% low fat 
dry milk-TBST (20 mM Tris, pH 7.5; 150 mM NaCl; 
0.05% Tween-20) using 1 pg/ml G1 antibody or the 
monoclonal pl20-ras-GAP and N-ras antibodies pur- 
chased from Santa Cruz Biotechnology (Santa Cruz, CA) 
and used according to their specifications. Detection was 
performed using the ECL kit from Amersham. 
Isoform Analysis 
Two micrograms of total RNA was reverse-tran- 
scribed using random hexamers and amplified by the 
polymerase chain reaction (PCR) using primers specific 
for the regions flanking exons 23a and 48a (Gutmann et 
al., 1993a,b). Equal amounts of exon 23a primer set 
products were separated by 10% PAGE and visualized 
with ethidium bromide staining (Gutmann et al., 1993a). 
Equal amounts of exon 48a primer set products were 
separated by 2% agarose electrophoresis and transferred 
onto Hybond membranes prior to probing with a 32P- 
labeled exon 48a oligonucleotide probe. These tech- 
niques have previously been described in detail (Gut- 
mann et al., 1993b). 
In Vivo p21-ras-GTP Assay 
Appropriately treated C,C, cells were grown in 
T-25 flasks and phosphate-starved for 2 hr prior to la- 
beling with 250-500 pCi; of 3ZP-orthophosphate (New 
England Nuclear, Boston, MA) for 4 hr at 37°C. The 
monolayer was rinsed twice with cold phosphate buff- 
ered saline (PBS), pH 8.0, and then lysed in 500 pliters 
of lysis buffer (20 mM Tris, pH 7.4; 100 mM NaCl; 20 
mM MgC1,; 1% NP-40; 0.5% sodium deoxycholate) 
containing 1 mM DTT and 1 %  aprotinin. Lysates were 
centrifuged for 10 min at 14 K rpm. The supernatant 
fraction was mixed with 50 pliters of 10% activated 
charcoal, centrifuged, and that supernatant incubated for 
2 hr with agitation with 60 pliters of protein 
A-Sepharose beads (50% suspension; Pharmacia) pre- 
coated with rabbit anti-rat antibodies (Sigma, St. Louis, 
MO) and 1-2 pg of Y13-259 rat monoclonal antibodies 
(Oncogene Science, Manhasset, NY). The beads were 
washed twice in buffer one (10 mM sodium phosphate, 
pH 7.6; 100 mM NaC1; 20 mM MgC1,; 1 mM EDTA; 
1% Triton X-100; 0.5% sodium deoxycholate; 0.1% 
SDS), twice in buffer two (20 mM Tris, pH 8.3; 250 mM 
NaC1; 20 mM MgCl,; 1% NP-40; 0.1% SDS), once 
again in buffer one, and then once in buffer three (10 mM 
Tris, pH 7.5; 20 mM MgC1,) prior to elution in 10 mM 
EDTA; 1% SDS; 20 pM GDP; 20 pM GTP at 65°C for 
of activated p21-ras (oncogenic p21-ras) resulted in the 
inhibition of both BC3H1 and C,C,, muscle cell differ- 
entiation (Olson et al., 1987; Payne et al., 1987; Gossett 
et al., 1988). Given the role of neurofibromin as a reg- 
ulator of p21-ras in Schwann cells, the relationship be- 
tween neurofibromin expression, p21-ras activation, and 
C,C,, cell differentiation was explored. In this report, 
we demonstrate the coordinate upregulation of neurofi- 
bromin expression and downrcgulation of activated p2 1 - 
ras during in vitro C,C,, muscle cell differentiation. 
MATERIALS AND METHODS 
Cell Culture 
C,C,, muscle cells were obtained from the ATCC 
(Rockville, MD) and grown in Dulbecco’s modified Ea- 
gle‘s medium (DMEM) containing 20% fetal bovine se- 
rum and 100 Uiml penicillin-streptomycin. These cells 
were passaged every 2-3 days before reaching greater 
than 80% confluency . Differentiation was initiated by 
changing the growth medium in cultures with at least 
80% confluency to DMEM containing 0.5% fetal bovine 
serum and 100 Uiml penicillin-streptomycin. 
Northern Blot Analysis 
Total RNA was extracted from C,C,, cultures ap- 
propriately treated using the RNAzol B protocol (Tel- 
Test, Inc., Friendswood, TX). Twenty micrograms of 
total RNA was electrophoretically separated on 1.2% 
agarose gels containing formaldehyde for 3.5-4 hr and 
transferred overnight in 20X SSC onto Hybond mem- 
branes (Amersham, Arlington Heights, IL) as previously 
described (Gutmann et al., 1993a). Blots were sequen- 
tially probed as previously described (Gutmann et al., 
1993a) with the 1.2 kb P5 probe (NFI gene) and the 950 
nt Pst 1 probe from the nicotinic acetylcholine receptor 
a-subunit gene (nAChR; generously provided by Dr. 
Dan Goldman, University of Michigan). Blots were 
stripped in boiling hot 0.1% sodium dodecyl sulfate 
(SDS) and 0.1 X Tris-EDTA for 20-30 min. 
Western Blot Analysis 
Total protein was extracted from C,C,, cultures 
appropriately treated in modified RIPA buffer (150 mM 
NaCl; 10 mM Tris, pH 7.5; 1% Triton X-100; 1% so- 
dium deoxycholate; 0.1% SDS; l mM EDTA) contain- 
ing 1 % aprotinin, 1 mM phenylmethylsulfonyl fluoride 
(PMSF), 1 mM dithiothreitol (DTT), and 1% leupeptin 
as previously described (Gutmann et al., 1993a). Protein 
concentrations were determined by the BioRad protein 
assay (New England BioLabs, Beverly, MA) as per the 
manufacturer’s instructions. Five hundred micrograms of 
total protein was separated by 12.5% SDS-polyacryl- 
amide gel electrophoresis (SDS-PAGE) followed by 
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5 min. Samples were separated on PEI chromatographic 
paper for 2.5 hr in 1.3 M lithium chloride and exposed by 
autoradiography. Quantitation was performed on a Mo- 
lecular Dynamics PhosphorImager 400E using Molecu- 
lar Dynamics TmageQuant software (Sunnyvale, CA). 
RESULTS 
N F l  mRNA Expression During In Vitro 
C,C,, Differentiation 
The differentiation of C,C,, myoblast cells into 
myotubes occurs after serum starvation (Schneider and 
Olson, 1988). Cells grown in medium containing 20% 
fetal bovine serum (FBS) are abruptly switched to me- 
dium containing 0.5% FBS and total RNA harvested at 
various time points thereafter. Morphological changes 
are apparent after 2 days in culture but are most pro- 
nounced at 3 days and beyond when myotubular struc- 
tures are evident. Unstimulated cells are kept at <80% 
confluency as some differentiation is evident when 
C,C,, cells approach 100% confluency. Total RNA was 
harvested, electrophoretically separated, and analyzed 
sequentially with the P5 N F f  cDNA probe and then the 
a-subunit of the nAChR probe as a marker of myoblast 
differentiation. A representative Northern blot is shown 
in Figure 1. As can be appreciated, there is coordinate 
upregulation of both the nAChR and N F l  by day 2 of 
C2C,, differentiation in vitro. However, the increase in 
nAChR expression precedes the expression of the NF1 
gene, suggesting that the NFI gene is not involved in the 
early stages of differentiation. Confluent cultures not 
subjected to serum starvation also demonstrated in- 
creased expression of both the nAChR and NFI (data not 
shown). This pattern of expression is similar to the up- 
regulation of the N-ras gene reported by others during 
C,C,, cell differentiation (Leibovitch et al., 1987). Sim- 
ilar results were also obtained using the BC,Hl cell line 
(data not shown). 
NF1 mRNA Isoform Expression During 
C,C,, Differentiation 
Previously we have shown that during in vitro 
Schwann cell differentiation, there is a change in the 
NFI isofonn expression (Gutmann et al., 1993a). Like- 
wise, during retinoic acid-induced neuroblastoma cell 
differentiation, a similar change is observed (Nishi et al., 
1991). To examine whether a change in NF1 isoform 
expression occurred with C,C, differentiation, total 
RNA was reverse-transcribed and amplified by PCR us- 
ing primers flanking the two alternative exons (23a and 
48a). As can be seen in Figure 2, there is no change in 
the expression of type 1 (lacking either insertion), 2 
(containing exon 23a), or 3 (containing exon 48a) N F f  
RNA. Likewise, no change in isoform expression was 
days in culture 
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Fig. 1. NFI mRNA expression during in vitro C,C,, differ- 
entiation. Twenty micrograms of total RNA was separated by 
agarose electrophoresis, transferred onto Immobilon mem- 
branes, and probed sequentially with NFI cDNA (P5) and 
a-subunit of the nAChR cDNA probes as described in Mate- 
rials and Methods. While low levels of nAChR mRNA are 
detectable in undifferentiated cells, the expression of NFI 
mRNA and increased expression of nAChR mRNA are seen by 
2 days in culture. The ethidium-stained membrane depicts the 
28s and 18s RNA bands. 
observed with 100% confluent cultures or differentiating 
BC,H1 cells (data not shown). No changes in overall 
expression of NF1 isoforms are observed since equal 
amounts of reverse-transcribed PCR products are loaded 
in each lane. 
Neurofibromin Expression During 
C,C,, Differentiation 
To confirm the N F f  RNA results on the protein 
level, the expression of neurofibromin was examined 
during the course of C,C,, differentiation. Total protein 
extracted from C2C,, cells was either immunoprecipi- 
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Fig. 2. N F l  mRNA isoform expression during C,C,, differ- 
entiation. Two micrograms of RNA was reverse-transcribed 
and amplified by PCR as described in Materials and Methods. 
NFI type 1 and type 2 [containing the exon 23a 63 nucleotide 
insertion into the GAP-related domain (GRD)] PCR products 
are photographed directly from ethidium bromide-stained 10% 
polyacrylamide gels. The 3'ALT isoform (containing the exon 
48a 54 nucleotide insertion into the extreme carboxyl terminus 
of the gene) is visualized by separating equivalent amounts of 
PCR products, transferring overnight to Immobilon mem- 
branes, and probing with the 48a exon-specific oligonucle- 
N-ras 
otide. Fig. 3 .  Neurofibromin expression during C2C,, differentia- 
tion. Total protein lysates taken from untreated CzCIz cells, 
differentiating C,C,, cells, or C,C,, cells grown to 100% con- 
tated first or simply electrophoretically separated, trans- fluency for days ("Dl were by immunob,otting. 
ferred Onto Imrnobilon membranes, and immunoblotted Two milligrams of total lysate was immunoprecipitated with 
with neurofibromin and N-ras antibodies. Previously it the neurofibromin ~1 peptide antisemm for 3-4 hr and col- 
was shown that N-ras mRNA levels rise during in vit1-0 lected on protein A-Sepharose beads and separated on 12.5% 
C,C,, differentiation (Leibovitch et al., 1987). Figure 3 SDS-polyacrylamide gels along with 500 pg of total lysate for 
depicts a representative experiment demonstrating thc 
coordinate rise of both neurofibromin and N-ras, but not 
pl20-ras-GAP, during C,C12 differentiation. Increased 
expression of neurofibromin and N-ras was also seen in 
100% confluent C,C,, cultures (labeled HD, Fig. 3), 
suggesting that cell contact can mimic some of the ef- 
fects of serum starvation in this cell line. These results 
were likewise seen on the RNA level (data not shown). 
Long-Term Differentiated C,CI2 Cultures Continue 
to Express Neurofibromin 
To determine whether the expression of neurofibro- 
min is a transient event during C,C,, differentiation, 
C,C, cells were serum-starved for 10-14 days after the 
morphological appearance of myotubular structures. 
RNA and protein were extracted and analyzed by North- 
ern and Western immunoblotting. As can be seen in 
Figure 4, there is continued expression of both NFZ 
mRNA and neurofibromin in long-term cultures at higher 
levels than observed at 3 days. This increased expression 
in long-term cultures most likely reflects the greater pro- 
plZGAP and N-ras immunoblotting. Ncurofibromin was de- 
tected by immunoblotting with neurofibromin G1 peptide an- 
tiserum (1 pg/ml). while N-ras and pl20-GAP were detected 
using monoclonal antisera as described in Materials and Meth- 
ods. 
portion of C,C, cells in 14 day cultures which have 
undergone terminal differentiation compared to 3 day 
cultures. The levels of N-ras and pl20-GAP do not re- 
producibly change during this interval in culture, despite 
minor variations observed between experiments. 
State of p21-ras-GTP During C2C,, Differentiation 
Previous work on both C,C, and BC,H1 cell lines 
has demonstrated that differentiation is inhibited by the 
introduction of activated oncogenic p2 1 -ras (Olson et al., 
1987; Payne et al., 1987; Gossett et al., 1988). This 
suggests that the process of C,C,, cell differentiation 
may be dependent on down-regulation of p2 1 -ras either 
by a net increase in total cellular GAP activity or a de- 
crease in total cellular guanosine nucleotide replacing 
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NFI mRNA 
days in culture 
14 3 0 --- 
-- 9.5 kb 




Fig. 4. NFI mRNA and neurofibromin expression with pro- 
longed C,C, cell differentiation. CzClz cells grown in 0.5% 
FBS-DMEM for 10-14 days after the appearance of myotu- 
bular structures were analyzed by Northern and Western blot- 
ting. For Northern blot analysis, 20 I J . ~  of total RNA was 
separated by agarose electrophoresis, transferred onto Immo- 
bilon membranes, and probed with NFI cDNA (P5) as de- 
scribed in Materials and Methods. For Western immunoblot- 
ting, 2 mg of total lysate was immunoprecipitated with the 
neurofibromin D1 peptide antiserum for 3-4 hr, collected on 
protein A-Sepharose beads, and separated on 12.5% SDS- 
polyacrylamide gels along with 500 p,g of total lysate for 
pl20-GAP and N-ras immunoblotting. Neurofibromin was de- 
tected by immunoblotting with neurofibromin GI peptide an- 
tiserum (1  pgiml), while N-ras and pl20-GAP were detected 
using monoclonal antisera as described in Materials and Meth- 
ods. 
factor activity. To examine whether the activation state 
of p21-ras changes during C,C,, differentiation, exper- 
iments were undertaken to examine the percent of GTP- 
bound p21 -ras (activated p21 -ras) during C,CI2 differ- 
entiation. The results of three such experiments are 
represented in Figure 5A. There is a significant decrease 
in the amount of activated GTP-bound p21-ras in C,CI2 
cells differentiating for 10 days in culture vs. proliferat- 
ing, but not confluent, C2CI2 cell cultures. Differenti- 
ated cultures (3-4 days of differentiation in 0.5% FBS- 
DMEM) also demonstrate low levels of activated p2 1 -ras 
(-22% GTP-bound p21-ras; data not shown). In these 
experiments, there is more p2 1 -ras precipitated from dif- 
ferentiated C,C , cells owing to the greater cell density 
in these cultures but the proportion of GTP-bound p21- 
ras decreases. The levels of GTP-bound p21-ras in our 
experiments are consistently higher than those observed 
by others (Basu et al., 1992; DeClue et al., 1992), but 
remain internally consistent, even with HeLa cell con- 
trols (Fig. 5B; data not shown). 
DISCUSSION 
The successful identification of the gene for NFI 
has opened the door for a more complete understanding 
of the role of neurofibromin in health and disease. The 
finding of one NFZ isoform containing an additional 54 
nucleotides (exon 48a) in muscle suggested that neurofi- 
bromin may play a unique role in muscle unrelated to the 
clinical disease. For this reason, an examination of NFI 
gene expression during muscle differentiation was initi- 
ated. NFI gene and neurofibromin expression are shown 
to be upregulated during C,C,, cell differentiation in 
vitro and this increase is paralleled by a decrease in the 
activation state of p21-ras. 
Although the role of neurofibromin in differentiat- 
ing cells is largely unknown, two properties of neurofi- 
bromin are well established. First, neurofibromin is a 
member of the GAP family of proteins and can accelerate 
the conversion of p21-ras from the active GTP-bound 
form to the inactive GDP-bound form (Ballester et al., 
1990; Martin et al., 1990; Xu et al., 1990). Lack of 
neurofibromin in some cell types is associated with ele- 
vated levels of GTP-bound activated p21-ras (Basu et 
al., 1992; DeClue et al., 1992). Second, neurofibromin 
associates with cytoplasmic microtubules in some cell 
types (Gregory et al., 1993). This association of tubulin 
(a component of microtubules) partially inhibits the abil- 
ity of neurofibromin to function effectively as a GAP 
molecule (Bollag et al., 1993). 
During cyclic AMP (CAMP)-induced Schwann cell 
differentiation and retinoic acid-induced neuroblastoma 
neuronal differentiation, there is a change in N F l  iso- 
form expression. In these studies, undifferentiated 
NFI Gene Expression in Muscle Differentiation 403 
change their pattern of isoform expression suggests that 
changes in neurofibromin function are entirely due to an 
increase in total neurofibromin. 
The observation that neurofibromin expression is 
dramatically increased during C,C,, cell differentiation 
suggests that the NF1 gene product may be part of this 
differentiation program. Previous studies on C,C 12 and 
BC,H 1 cell lines have demonstrated that overexpression 
of activated p21-ras (N-ras or H-ras) blocks myoblast 
differentiation (Olson et al., 1987; Payne et al., 1987; 
Gossett et al., 1988) by inhibiting MyoDl and myogenin 
expression through transcriptional regulation (Lassar et 
al., 1989). However, the relationship between increased 
20 0.5 neurofibromin expression, decreased p2 1 -ras activation, 
and C,C,, muscle cell differentiation may be more com- 
plicated. Three possibilities can be envisioned. One 
model has increased neurofibromin expression and de- 
creased levels of activated p21-ras as unrelated events 
common to the C2C,, differentiation program. This im- 
plies that the decrease in GTP-bound p21-ras is not re- 
lated to an overexpression of neurofibromin, but rather to 
another event. Similarly, it is possible that p21-ras 
through its interactions with other proteins actually reg- 
ulates N F l  gene expression. In yeast cells, RAS acti- 
vates adenylate cyclase and results in an increase in 
cAMP (Broach, 1991). In Schwann cells, increasing the 
levels of intracellular cAMP is associated with increased 
neurofibromin expression (Gutmann et al., 1993a). This 
increased NFl gene expression may therefore be related 
% fetal bovine serum 
0.5% FBS 20% FRS 




Fig. 5 .  State of p21-ras-GTP during C2CI2 differentiation. In 
vivo p2 1-ras-GTP assays were performed on undifferentiated 
C,C12 cells grown at 75-80% confluency or differentiated 
C2C,2 cells grown for 10-12 days of serum starvation. A: Each 
data point represents the mean and standard deviation for three 
separate experiments. B: PhosphorImage analysis of a repre- 
sentative experiment demonstrating the amount of GTP and 
GDP eluted from p2 1 -ras immunoprecipitates of undifferenti- 
ated and differentiated C2Cl, cells resolved by PEI chroma- 
tography. 
Schwann cells express predominantly type 1 N F l  (lack- 
ing the 63 nucleotide insertion into the GAP-related do- 
main of N F l ) ,  while differentiating cells express pre- 
dominantly the type 2 form with this insertion (Gutmann 
et al., 1993a). Similar results have been obtained using 
SH-SYSY neuroblastoma cells in response to retinoic 
acid stimulation (Nishi et al., 199 1 ). The presence of this 
insertion in the GAP-related domain of neurofibromin 
has been shown to dramatically reduce the ability of 
neurofibromin to function as a GAP molecule (Andersen 
et al., 1993) and may alter its association with cytoplas- 
mic microtubules (Gutmann et al . ,  manuscript in prepa- 
ration). The fact that differentiating C,C,, cells do not 
to the presence-of a putative CAMP-responsive element 
in the 5’-untranslated region of the NFI gene (Hajra et 
al., manuscript in preparation). 
A second model envisions that the increase in neu- 
rofibromin expression results in a decrease in activated 
GTP-bound p2 1 -ras by accelerating the conversion of 
p2 1 -ras-GTP to p2 1 -ras-GDP. This is a tantalizing notion 
which will need to be addressed in future studies aimed 
at determining the effect of neurofibromin overexpres- 
sion on C,C,, differentiation and p21-ras-GTP levels. To 
demonstrate a causal relationship between neurofibromin 
expression, p2 1 -ras activation, and C,C ,, cell differen- 
tiation, we attempted to examine the effects of upregu- 
lating and downregulating N F l  gene expression. Exper- 
iments in which the GAP regulatory domain of 
neurofibromin (NFlGRD) was stably transfected into 
C,C I , cells failed to yield clones overexpressing neurofi- 
bromin yet were clearly resistant to G418 (neomycin): In 
two experiments, 20 individual G4 1 8-resistant colonies 
and in two other experiments, two pools of 40 G418- 
resistant colonies each were examined for NFlGRD ex- 
pression. None of these samples expressed NFlGRD 
protein. It is possible that this failure reflects activation 
of the C,C,, cell differentiation program and loss of 
these neurofibromin-expressing cells from the dividing 
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G418-resistant population. The construction of a suitable 
inducible expression vector is now in progress to exam- 
ine this possibility. Likewise, efforts at downregulating 
neurofibromin expression using phosphorothioate an- 
tisense and control sense oligonucleotides were unsuc- 
cessful at modulating NFI expression. It is most likely 
that neurofibromin expression is related to the C,C,, cell 
differentiation program, but is not required for its initi- 
ation or early commitment. 
A third model envisions that the increase in neu- 
rofibromin and reduction of activated p21 -ras are related 
to cell density effects and not differentiation. This pos- 
sibility, although unlikely given the activated p21 -ras 
experiments, cannot be excluded at this time. The exam- 
ination of non-fusing variants for changes in neurofibro- 
min levels and p21-ras activation under high and low 
density conditions as well as the effects of transforming 
growth factor beta (TGF-P) on the expression of neurofi- 
bromin will help to address this issue. 
Previous work by a number of laboratories have 
demonstrated that there is little neurofibromin expressed 
in adult cardiac and skeletal muscle (Daston et al., 1992; 
Golubic et al., 1992). However, there is expression of 
neurofibromin in the developing heart and myotomes of 
chicks and mice (Daston and Ratner, 1992; Barald, per- 
sonal communication, 1993). This expression is lost later 
during fetal development. Mice made homozygousl y de- 
ficient in NFI gene expression by targeted gene disrup- 
tion develop cardiac developmental defects (Shih, Jacks, 
and Weinberg, personal communication). These obser- 
vations suggest that neurofibromin expression might be 
important in muscle development. Future studies di- 
rected at examining the role of neurofibromin during in 
vivo muscle differentiation and regeneration will provide 
invaluable insights into the function of this tumor sup- 
pressor gene product. 
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